5 Reasons This Growth Stock Is Up 23% So Far in 2019
Danaher's management continues to transform the conglomerate, and the GE Biopharma deal looks like an even better value after a recent disclosure.
via FOX BUSINESS NEWS https://fxn.ws/2XRvcEa
Saturday, April 27, 2019
FOX BIZ NEWS: 5 Reasons This Growth Stock Is Up 23% So Far in 2019
5 Reasons This Growth Stock Is Up 23% So Far in 2019
Danaher's management continues to transform the conglomerate, and the GE Biopharma deal looks like an even better value after a recent disclosure.
via FOX BUSINESS NEWS https://fxn.ws/2XRvcEa
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment